Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOROTCMKTS:PXSLYOTCMKTS:TBUFFNASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.47$0.87$0.55▼$4.42$105.18M-0.071.09 million shs129,106 shsPXSLYPharmaxis$0.88$0.88$0.62▼$1.47$26.53M1.221,000 shsN/ATBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsZNTLZentalis Pharmaceuticals$1.34-8.2%$1.32$1.01▼$8.87$96.42M1.611.57 million shs1.02 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology0.00%+39.99%+60.66%+150.00%+146,999,900.00%PXSLYPharmaxis0.00%0.00%0.00%0.00%0.00%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%ZNTLZentalis Pharmaceuticals0.00%-11.84%+6.35%-29.10%-84.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/AZNTLZentalis Pharmaceuticals2.3112 of 5 stars3.22.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.00Hold$3.00104.08% UpsidePXSLYPharmaxis 0.00N/AN/AN/ATBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/AZNTLZentalis Pharmaceuticals 2.44Hold$8.24515.26% UpsideCurrent Analyst Ratings BreakdownLatest PXSLY, TBUFF, CTOR, and ZNTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.005/15/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.003/27/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/17/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/APXSLYPharmaxis$8.75M3.03N/AN/A$0.04 per share22.00TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AZNTLZentalis Pharmaceuticals$26.87M3.59N/AN/A$6.18 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/APXSLYPharmaxis-$9.36MN/A0.00∞N/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/AZNTLZentalis Pharmaceuticals-$292.19M-$3.13N/AN/AN/AN/A-43.91%-34.96%8/8/2025 (Estimated)Latest PXSLY, TBUFF, CTOR, and ZNTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/14/2025Q1 2025ZNTLZentalis Pharmaceuticals-$0.67-$0.67N/A-$0.67N/AN/A3/26/2025Q4 2024ZNTLZentalis Pharmaceuticals-$0.75-$0.66+$0.09-$0.66N/A$26.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.080.340.08PXSLYPharmaxis2.823.312.92TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AZNTLZentalis PharmaceuticalsN/A7.297.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%PXSLYPharmaxisN/ATBUFFTribute Pharmaceuticals CanadaN/AZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCTORCitius Oncology4.57%PXSLYPharmaxisN/ATBUFFTribute Pharmaceuticals CanadaN/AZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/APXSLYPharmaxis6930.15 millionN/ANot OptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableZNTLZentalis Pharmaceuticals16071.95 million68.70 millionOptionablePXSLY, TBUFF, CTOR, and ZNTL HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DEJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)June 3, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Two Sigma Advisers LPMay 29, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Lessened by Woodline Partners LPMay 27, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by AnalystsMay 25, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Takes $703,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 20, 2025 | marketbeat.comHC Wainwright Brokers Raise Earnings Estimates for ZNTLMay 20, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for ZNTL EarningsMay 20, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comZentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational ProgressMay 14, 2025 | globenewswire.comFirst Patient Dosed With Azenosertib in Cyclin E1+ Ovarian CancerMay 3, 2025 | curetoday.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comScott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) StockMay 1, 2025 | insidertrades.comZentalis shares insights on cancer research at AACRApril 29, 2025 | investing.comZentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROCApril 28, 2025 | globenewswire.comZentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comWhy Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%April 10, 2025 | aaii.comWhy Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%April 2, 2025 | aaii.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comStifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)March 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking StocksPXSLY, TBUFF, CTOR, and ZNTL Company DescriptionsCitius Oncology NASDAQ:CTOR$1.47 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.45 -0.02 (-1.36%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Pharmaxis OTCMKTS:PXSLY$0.88 0.00 (0.00%) As of 06/8/2021Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.34 -0.12 (-8.22%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.38 +0.03 (+2.61%) As of 06/13/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
